Global Bronchoscopy Market Size, Trends, Analysis and Forecast 2027

The Global Bronchoscopy Market in terms of revenue was estimated to be worth $2.5 billion in 2022 and is poised to reach $3.7 billion by 2027, growing at a CAGR of 7.9% from 2022 to 2027. Market growth is largely driven by the rising prevalence of respiratory diseases, growing hospital investments in bronchoscopy facilities, and technological improvement in bronchoscopes. On the other hand, risk associated with the bronchoscopy procedures is a major restrains to the growth of this market.

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40057877

Bronchoscopy Market Dynamics

Drivers: Rising prevalence of respiratory diseases

The prevalence of various respiratory diseases, such as lung cancer, asthma, COPD, and emphysema, is on the rise globally. Chronic obstructive pulmonary disease (COPD) and asthma are the most prevalent respiratory disorders across the globe. According to the report published by Lancet, there were 391 million cases of COPD worldwide in 2019 among adults aged 30-79. According to the WHO, COPD is expected to become the world’s third-biggest health threat by 2030. Some of the major causes of COPD are long-term asthma and prolonged exposure to tobacco smoke, indoor and outdoor air pollution, and occupational fumes and dust. According to the WHO, about 262 million people suffer from asthma. The disease resulted in 455,000 deaths in 2019.

Restraints: High overhead cost of bronchoscopy procedures

According to a thorough analysis, the price per case for reusable flexible bronchoscopes (RFBs) and single-use flexible bronchoscopes (SUFBs) was USD 281–803 and USD 220–315, respectively. The average cost of maintenance and repair of reusable bronchoscopes is USD 2,524 per bronchoscope per year. Two therapeutic RFBs have an average age of 6.38 years and have repair costs of USD 90,658 in total. The second smallest RFB (Olympus BF-P190) had the greatest single-scope repair cost of USD 72,009. Two of the diagnostic RFBs were greater than 12 years old and had no repair costs. This finding likely reflects minimal to no usage, as opposed to impressive durability. Data on the number of times each individual bronchoscope was used are unavailable. During the three-year period in question, approximately 4,500 flexible bronchoscopies were performed with these RFBs. This translates into repair costs of about USD 62 per case. With the availability of disposable bronchoscopes, low-volume centers are most likely to achieve cost savings. Healthcare providers—particularly in developing countries such as India, Brazil, and Mexico—have low financial resources to invest in such costly technologies. Moreover, the staff should be trained for the efficient handling and maintenance of bronchoscopy systems and equipment. Maintaining bronchoscopy equipment is of vital importance as improperly reprocessed bronchoscopes can lead to cross-contamination and potentially expose patients to infections. This can incur additional costs. Moreover, constant heating and cooling during disinfection procedures can cause wear and tear on the insertion and light guide tubes, which can hamper the durability of bronchoscopy equipment. All these factors add to the cost of bronchoscopy procedures.

Request Free Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=40057877

The flexible bronchoscopes are accounted to hold the highest CAGR of the bronchoscopy industry, by product during forecasted period.

Based on product, the bronchoscopy equipment market is segmented into bronchoscopes, imaging systems, accessories, and other bronchoscopy equipment. The bronchoscopes segment accounted for the highest CAGR of the bronchoscopy equipment market in 2021. The highest CAGR of this segment can be attributed to the high cost of bronchoscopes compared to imaging systems and accessories, the increasing prevalence of lung cancer, and technological advancements

The disposable equipments are accounted to hold the highest CAGR of the bronchoscopy market, by usability during forecasted period.

Based on usability, the bronchoscopy equipment market is segmented into reusable equipment and disposable equipment. The highest CAGR of this segment can be attributed to the risk of infection associated with the use of reusable equipment has driven attention toward disposable equipment and is the major factor driving market growth in this segment, particularly given the increasing demand for minimally invasive techniques with the growing threat of multidrug antibiotic resistance

The adult patients are accounted to hold the highest CAGR of the bronchoscopy market, by patients forecasted period.

Based on On the basis of patients, the bronchoscopy equipment market is segmented into adult patients and pediatric patients. The adult patients segment accounted for the highest CAGR of the bronchoscopy equipment market forecasted period. The highest CAGR of this segment can be attributed to the high image quality achieved through reusable bronchoscopes and the availability of reusable accessories.

North America accounted the largest share of the bronchoscopy industry in 2021.

The large share of the North American market can be attributed to the increasing incidence and prevalence of chronic respiratory diseases, favorable reimbursement scenario in the US, the rising incidence of lung cancer in Canada, rapid increase in healthcare expenditure, easy accessibility to advanced technologies, and the strong presence of market players in the region

Key Players:

Corporation (Japan), KARL STORZ (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Ethicon (US), FUJIFILM Holdings Corporation (Japan), Medtronic (Ireland), HOYA Corporation (Japan), Richard Wolf GmbH (Germany), Cook Medical (US), Broncus Medical Inc. (China), CONMED (US), Roper Technologies (US), Teleflex Incorporated (US), Laborie Medical Technologies Corp. (Canada), EFER Endoscopy (France), EMOS Technology GmbH (Germany), VBM Medizintechnik GmbH (Germany), Hunan Vathin Medical Instrument Co., Ltd. (China), and Machida Endoscope Co., Ltd. (China)

Key developments:

In 2022, Ethicon, a Johnson Johnson MedTech firm, declared today that the FDA granted 510(k) approval for its Monarch robotic surgery platform. The FDA has given Ethicon’s subsidiary Auris Health permission to use Monarch for endourological treatments. According to company representatives, it is currently the first and only versatile multispecialty robotic solution for use in both urology and bronchoscopy
In 2022, Olympus announced the expansion of its respiratory portfolio with the launch of H-SteriScopes. In order to address the demands of infection prevention campaigns, Olympus announced the availability of its line of single-use foreign body retrieval devices, which gives doctors alternatives for a variety of purposes.
In 2021, The EXALT Model B Single-use Bronchoscope, a single-use device intended for bedside operations in the intensive care unit, operating room, and bronchoscopy suite, received CE Mark approval
In 2022, Olympus announced the strategic co-marketing agreement with Bracco Diagnostics Inc., which is a US subsidiary of Bracco Imaging S.p.A., a major international player in the diagnostic imaging industry. Bracco Imaging S.p.A. is a leader in the creation and delivery of new solutions for medical and surgical operations.
In 2022, Olympus announced that its line of single-use bronchoscopes had been selected for the new Vizient Single-use Visualization Devices contract.
In 2021, FUJIFILM Holdings Corporation announced that its complete portfolio of endoscopy and endosurgery products is available to members of Vizient.

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=40057877

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: 1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/bronchoscopes-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/bronchoscopes.asp

Related Reports: